Profile data is unavailable for this security.
About the company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
- Revenue in USD (TTM)2.24m
- Net income in USD-42.19m
- Incorporated2020
- Employees57.00
- LocationSAB Biotherapeutics Inc2100 East 54Th Street North, Suite 202SIOUX FALLS 57104United StatesUSA
- Phone+1 (605) 679-6980
- Fax+1 (302) 636-5454
- Websitehttps://www.sab.bio/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DURECT Corp | 8.55m | -27.62m | 35.07m | 58.00 | -- | 2.32 | -- | 4.10 | -1.12 | -1.12 | 0.3257 | 0.4873 | 0.1624 | 0.7927 | 3.65 | 147,379.30 | -52.47 | -37.34 | -124.79 | -53.44 | 79.91 | 91.83 | -323.16 | -139.11 | 1.20 | -55.63 | 0.5299 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
CASI Pharmaceuticals Inc | 33.88m | -26.96m | 35.15m | 176.00 | -- | 1.45 | -- | 1.04 | -2.02 | -2.02 | 2.54 | 1.81 | 0.3951 | 1.26 | 3.01 | 192,494.30 | -30.57 | -34.75 | -45.42 | -46.91 | 59.19 | 55.98 | -77.37 | -153.72 | 2.60 | -- | 0.4388 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
Nuo Therapeutics Inc | 608.53k | -3.17m | 35.39m | -- | -- | 34.06 | -- | 58.16 | -0.0754 | -0.0754 | 0.0145 | 0.0235 | 0.2471 | 0.5609 | 3.55 | -- | -128.78 | -116.16 | -173.76 | -354.84 | 79.28 | 70.02 | -521.17 | -854.53 | 2.01 | -1,002.61 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Apollomics Inc | 0.00 | -388.09m | 35.49m | -- | -- | 0.6372 | -- | -- | -4.34 | -4.34 | 0.00 | 0.6225 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,391.69 | 0.012 | -- | -- | -- | -154.03 | -- | -- | -- |
NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 36.80m | 1.00 | -- | 0.2055 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
SAB Biotherapeutics Inc | 2.24m | -42.19m | 36.90m | 57.00 | -- | 0.644 | -- | 16.48 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Janone Inc | 0.00 | -17.10m | 37.16m | 5.00 | -- | -- | -- | -- | -3.52 | -0.4564 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.40 | -23.12 | -96.58 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.0594 | -- | -- | -- | -313.15 | -- | -- | -- |
Vyne Therapeutics Inc | 424.00k | -27.87m | 37.36m | 10.00 | -- | 0.421 | -- | 88.12 | -6.84 | -7.00 | 0.0413 | 6.29 | 0.0061 | -- | 0.1639 | 42,400.00 | -40.27 | -108.41 | -45.86 | -138.57 | -- | -- | -6,573.82 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
Unicycive Therapeutics Inc | 675.00k | -31.41m | 37.54m | 14.00 | -- | -- | -- | 55.61 | -1.62 | -1.62 | 0.0276 | -0.1096 | 0.0794 | -- | -- | 48,214.29 | -359.15 | -218.20 | -- | -609.54 | -- | -- | -4,525.04 | -3,877.49 | -- | -- | -- | -- | -29.02 | -- | -73.95 | -- | -- | -- |
Marker Therapeutics Inc | 3.31m | -14.05m | 37.70m | 8.00 | -- | 2.68 | -- | 11.39 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Earth Science Tech Inc | 5.98m | 330.94k | 37.78m | 8.00 | 125.00 | 17.50 | 71.39 | 6.31 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
Palatin Technologies, Inc. | 7.10m | -30.91m | 37.92m | 34.00 | -- | -- | -- | 5.34 | -2.48 | -2.48 | 0.5582 | -0.7956 | 0.3118 | 0.8717 | 3.42 | 208,755.90 | -135.79 | -26.11 | -269.84 | -30.68 | 95.34 | -- | -435.53 | -126.20 | 1.09 | -- | -- | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
OncoCyte Corp | 1.50m | -25.80m | 38.36m | 43.00 | -- | 1.16 | -- | 25.52 | -3.08 | -3.47 | 0.1869 | 3.10 | 0.0172 | -- | 1.20 | 34,953.49 | -28.41 | -35.11 | -31.93 | -39.71 | 27.48 | -- | -1,653.69 | -2,373.36 | -- | -146.07 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Movano Inc | 0.00 | -29.28m | 38.80m | 30.00 | -- | 6.39 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
Holder | Shares | % Held |
---|---|---|
RTW Investments LPas of 31 Dec 2023 | 917.83k | 9.95% |
BVF Partners LPas of 31 Dec 2023 | 917.83k | 9.95% |
Marshall Wace LLPas of 31 Dec 2023 | 458.53k | 4.97% |
Sessa Capital IM LPas of 18 Mar 2024 | 458.46k | 4.97% |
RA Capital Management LPas of 31 Dec 2023 | 237.41k | 2.57% |
Commodore Capital LPas of 31 Dec 2023 | 183.18k | 1.99% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 98.48k | 1.07% |
Pathstone Family Office LLCas of 31 Dec 2023 | 50.65k | 0.55% |
Geode Capital Management LLCas of 31 Dec 2023 | 35.64k | 0.39% |
First Manhattan Co LLCas of 31 Dec 2023 | 27.78k | 0.30% |